Leveraging strong R&D platforms, Innovent has built a robust pipeline of 25 clinical-stage assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 5 products, including Tyvyt (sintilimab injection, PD-1 antibody), Byvasda (bevacizumab injection), Sulinno (adalimumab injection) and Halpryza (rituximab injection) approved by the National Medicine Products Administration (NMPA) for marketing in Mainland China and IBI375 (Pemigatinib, FGFR1/2/3 inhibitor) approved by Taiwan Food and Drug Administration (TFDA), 6 assets in pivotal clinical trials, and additional 14 molecules in early clinical stage.

The cloud communication platform includes varied types of solutions which are used to boost the efficiency of business activities. Unified Communication and Collaboration (UCC/UCaaS), Web Real-Time Communication (WebRTC), Interactive Voice Response (IVR), Voice Over Internet Protocol (VoIP), Application Programming Interface (API) are some of the prominent solutions used by industries to increase the effectiveness of operations. Ion addition, with an increase in remote working and work from policy, the penetration of cloud based platforms are boosting at an exponential rate.